Oxford Vaccine Elderly
- All
- News
- Videos
-
Pfizer, Oxford Vaccines Reduce Severe COVID-19 In Elderly, UK Study Finds
The Pfizer and Oxford-AstraZeneca vaccines for COVID-19 are highly effective in reducing severe coronavirus infection among people aged 70 years and above, according to a study.
-
Pfizer, Oxford Covid Vaccines "Highly Effective" In Elderly: UK Study
The Pfizer and Oxford-AstraZeneca vaccines have been "highly effective" in reducing coronavirus infections and severe illness among elderly people in Britain, with a more than 80 percent reduction in hospitalisation, official data showed Monday.
-
Extra Data Shows AstraZeneca Vaccine Efficacy In Elderly: UK Regulators
British regulators have received extra trial data from AstraZeneca that supports their view that the COVID-19 vaccine developed with Oxford University is effective in the elderly, a vaccines official said on Friday
-
Oxford Vaccine Gives Good Immune Responses In Elderly, Says Trial Chief
The COVID-19 vaccine developed by Oxford University and AstraZeneca gives good immune responses in older people, even if there is a lack of data about its exact efficacy, Oxford's vaccine trial chief Andrew Pollard said on Wednesday.
-
Oxford Vaccine Likely By April 2021, Rs 1,000 For 2 Doses: Adar Poonawalla
Vaccine maker Serum Institute of India's CEO Adar Poonawalla on Thursday said the Oxford COVID-19 vaccine should be available for healthcare workers and elderly people by around February 2021 and by April for the general public, and will be priced at a maximum of Rs 1,000 for two necessary doses for the public, depending on the final trial results ...
-
Oxford Vaccine Safe, Even The Elderly Responding: Serum Institute Chief
The Oxford University's Covishield vaccine for coronavirus has drawn an immune response even in the elderly, who are among the groups vulnerable to the disease, Adar Poonawala, the chief of Serum Institute of Imdia, which is partnering the UK-based premier university, told NDTV today. The vaccine, he said, is "very safe". "Thousands of people have ...
-
Oxford Covid Vaccine Draws Immune Response Among Young, Old: AstraZeneca
The COVID-19 vaccine being developed by the University of Oxford produces an immune response in both elderly and young people and adverse reactions were lower among the elderly, British drug maker AstraZeneca Plc said on Monday.
-
Oxford COVID-19 Vaccine Trials Produce Robust Immune Response In Elderly: Report
The COVID-19 vaccine being developed by the University of Oxford produces a similar immune response in both older and younger adults, and adverse responses were lower among the elderly, British drug maker AstraZeneca Plc said on Monday.
-
Pfizer, Oxford Vaccines Reduce Severe COVID-19 In Elderly, UK Study Finds
The Pfizer and Oxford-AstraZeneca vaccines for COVID-19 are highly effective in reducing severe coronavirus infection among people aged 70 years and above, according to a study.
-
Pfizer, Oxford Covid Vaccines "Highly Effective" In Elderly: UK Study
The Pfizer and Oxford-AstraZeneca vaccines have been "highly effective" in reducing coronavirus infections and severe illness among elderly people in Britain, with a more than 80 percent reduction in hospitalisation, official data showed Monday.
-
Extra Data Shows AstraZeneca Vaccine Efficacy In Elderly: UK Regulators
British regulators have received extra trial data from AstraZeneca that supports their view that the COVID-19 vaccine developed with Oxford University is effective in the elderly, a vaccines official said on Friday
-
Oxford Vaccine Gives Good Immune Responses In Elderly, Says Trial Chief
The COVID-19 vaccine developed by Oxford University and AstraZeneca gives good immune responses in older people, even if there is a lack of data about its exact efficacy, Oxford's vaccine trial chief Andrew Pollard said on Wednesday.
-
Oxford Vaccine Likely By April 2021, Rs 1,000 For 2 Doses: Adar Poonawalla
Vaccine maker Serum Institute of India's CEO Adar Poonawalla on Thursday said the Oxford COVID-19 vaccine should be available for healthcare workers and elderly people by around February 2021 and by April for the general public, and will be priced at a maximum of Rs 1,000 for two necessary doses for the public, depending on the final trial results ...
-
Oxford Vaccine Safe, Even The Elderly Responding: Serum Institute Chief
The Oxford University's Covishield vaccine for coronavirus has drawn an immune response even in the elderly, who are among the groups vulnerable to the disease, Adar Poonawala, the chief of Serum Institute of Imdia, which is partnering the UK-based premier university, told NDTV today. The vaccine, he said, is "very safe". "Thousands of people have ...
-
Oxford Covid Vaccine Draws Immune Response Among Young, Old: AstraZeneca
The COVID-19 vaccine being developed by the University of Oxford produces an immune response in both elderly and young people and adverse reactions were lower among the elderly, British drug maker AstraZeneca Plc said on Monday.
-
Oxford COVID-19 Vaccine Trials Produce Robust Immune Response In Elderly: Report
The COVID-19 vaccine being developed by the University of Oxford produces a similar immune response in both older and younger adults, and adverse responses were lower among the elderly, British drug maker AstraZeneca Plc said on Monday.
